Here’s Who Just Picked Up OFS Capital Corp (NASDAQ:OFS) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), OFS Capital Corp (NASDAQ:OFS) reported that Ofs Capital Corp has picked up 2,946,474 of common stock as of 2017-04-11.
The acquisition brings the aggregate amount owned by Ofs Capital Corp Advisors to a total of 2,946,474 representing a 22.3% stake in the company.
For those not familiar with the company, OFS Capital Corporation (OFS Capital) is an externally managed, closed-end, non-diversified management investment company. The Company’s investment objective is to provide its shareholders with both current income and capital appreciation primarily through debt investments and equity investments. It focuses primarily on middle-market companies in the United States, including senior secured loans, including first-lien, second-lien and unitranche loans, as well as subordinated loans, and warrants and other minority equity securities. The Company may make investments directly or through OFS SBIC I, LP (SBIC I LP), its investment company subsidiary. It focuses on investments in loans, in which OFS Advisor’s investment professionals have expertise, including investments in first-lien, unitranche, second-lien, and mezzanine loans and, to a lesser extent, on warrants and other equity securities. The Company’s investment activities are managed by OFS Capital Management, LLC (OFS Advisor).
A glance at OFS Capital Corp (NASDAQ:OFS)’s key stats reveals a current market capitalization of 136.98 Million based on 9.70 Million shares outstanding and a price at last close of $14.30 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2014-08-27, Pittson picked up 12,965 at a purchase price of $12.75. This brings their total holding to 80,031 as of the date of the filing.
On the sell side, the most recent transaction saw Rubenfeld unload 1,000 shares at a sale price of $11.02. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on OFS Capital Corp (NASDAQ:OFS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
See who picked Bellicum Pharmaceuticals (NASDAQ:BLCM)
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) reported that Baker Bros. Advisors has picked up 5,032,313 of common stock as of 2017-04-11.
The acquisition brings the aggregate amount owned by Baker Bros. Advisors to a total of 5,032,313 representing a 15.2% stake in the company.
For those not familiar with the company, Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-601 and BPX-701. The Company’s CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
A glance at Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM)’s key stats reveals a current market capitalization of 457.66 Million based on 32.16 Million shares outstanding and a price at last close of $12.86 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-24, Baker picked up 151,177 at a purchase price of $12.00. This brings their total holding to 4,527,089 as of the date of the filing.
On the sell side, the most recent transaction saw Slawin unload 30,000 shares at a sale price of $12.54. This brings their total holding to 294,982.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.